IS8071A - Aðferð við meðhöndlun á hnútahersli, fitudreyra og tengdum ástands tegundum og lyfjafræðilegum samsetningum - Google Patents

Aðferð við meðhöndlun á hnútahersli, fitudreyra og tengdum ástands tegundum og lyfjafræðilegum samsetningum

Info

Publication number: IS8071A
Authority: IS; Iceland
Prior art keywords: liposuction; scoliosis; nodular; treatment; pharmaceutical compositions
Prior art date: 2003-05-15

Application number

IS8071A

Other languages

English (en)

Other versions

IS2708B (is

Inventor

Cheng Kang

M. Waters Gerard

M. Metters Kathleen

O'neill Gary

Original Assignee

Merck & Co., Inc.

Merck Frosst Canada Ltd.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-05-15

Filing date

2005-10-13

Publication date

2005-10-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33476734&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS8071(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-10-13 Application filed by Merck & Co., Inc., Merck Frosst Canada Ltd. filed Critical Merck & Co., Inc.

2005-10-13 Publication of IS8071A publication Critical patent/IS8071A/is

2011-01-15 Publication of IS2708B publication Critical patent/IS2708B/is

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Indole Compounds (AREA)
Medicines Containing Plant Substances (AREA)

IS8071A 2003-05-15 2005-10-13 Aðferð til að meðhöndla hnútahersli, blóðfituröskun og tengdar ástandstegundir og lyfjasamsetningar IS2708B (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US47066503P	2003-05-15	2003-05-15
PCT/US2004/014980 WO2004103370A1 (en)	2003-05-15	2004-05-13	Method of treating atherosclerosis, dyslipidemias and related conditions and pharmaceutical compositions

Publications (2)

Publication Number	Publication Date
IS8071A true IS8071A (is)	2005-10-13
IS2708B IS2708B (is)	2011-01-15

Family

ID=33476734

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS8071A IS2708B (is)	2003-05-15	2005-10-13	Aðferð til að meðhöndla hnútahersli, blóðfituröskun og tengdar ástandstegundir og lyfjasamsetningar

Country Status (44)

Country	Link
US (4)	US20040229844A1 (is)
EP (3)	EP1624871B1 (is)
JP (2)	JP4637833B2 (is)
KR (2)	KR100806008B1 (is)
CN (3)	CN100441184C (is)
AR (1)	AR041089A1 (is)
AU (2)	AU2004240597B2 (is)
BR (1)	BRPI0410273A (is)
CA (1)	CA2525772C (is)
CL (1)	CL2004001056A1 (is)
CO (1)	CO5630034A2 (is)
CR (2)	CR8047A (is)
CY (2)	CY1109476T1 (is)
DE (1)	DE602004022036D1 (is)
DK (2)	DK1624871T3 (is)
DO (1)	DOP2004000907A (is)
EA (2)	EA011895B1 (is)
EC (1)	ECSP056156A (is)
ES (2)	ES2392743T3 (is)
GE (2)	GEP20084569B (is)
GT (1)	GT200400098A (is)
HN (1)	HN2004000171A (is)
HR (2)	HRP20090424T1 (is)
IL (1)	IL171962A (is)
IS (1)	IS2708B (is)
JO (1)	JO2564B1 (is)
MA (1)	MA27835A1 (is)
ME (1)	MEP60108A (is)
MX (1)	MXPA05012272A (is)
MY (1)	MY140639A (is)
NO (1)	NO20055957L (is)
NZ (2)	NZ543399A (is)
PA (1)	PA8603201A1 (is)
PE (1)	PE20050552A1 (is)
PL (2)	PL1624871T3 (is)
PT (2)	PT1624871E (is)
RS (3)	RS20120499A1 (is)
SG (1)	SG153667A1 (is)
SI (2)	SI1624871T1 (is)
TN (1)	TNSN05290A1 (is)
TW (2)	TWI334354B (is)
UA (1)	UA89615C2 (is)
WO (1)	WO2004103370A1 (is)
ZA (1)	ZA200508288B (is)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4279561B2 (ja) *	2001-05-23	2009-06-17	メルクフロストカナダリミテツド	プロスタグランジンＤ２受容体拮抗薬としてのジヒドロピロロ［１，２−ａ］インドールおよびテトラヒドロピリド［１，２−ａ］−インドール誘導体
EP1603585A2 (en) *	2003-03-14	2005-12-14	Bristol-Myers Squibb Company	Polynucleotide encoding a novel human g-protein coupled receptor variant of hm74, hgprbmy74
PE20050483A1 (es)	2003-10-31	2005-08-25	Arena Pharm Inc	Derivados de tetrazol de formula (i), sus composiciones farmaceuticas y procesos para producir composiciones farmaceuticas
US7019022B2 (en) *	2003-12-15	2006-03-28	Merck Frosst Canada & Co.	Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
ES2582942T3 (es)	2004-10-08	2016-09-16	Forward Pharma A/S	Composiciones farmacéuticas de liberación controlada que comprenden un éster de ácido fumárico
PE20060949A1 (es)	2004-12-23	2006-10-11	Arena Pharm Inc	Derivados fusionados de pirazol como agonistas del receptor de niacina
US8165517B2 (en) *	2005-01-19	2012-04-24	The Trustees Of The University Of Pennsylvania	Methods for identifying inhibitors of vascular injury
CN101189011A (zh) *	2005-02-17	2008-05-28	默克公司	治疗动脉粥样硬化、脂质异常和相关状况的方法
JP2008538277A (ja) *	2005-02-18	2008-10-23	アリーナファーマシューティカルズ，インコーポレイテッド	脂質関連障害の治療用の組成物および方法
US7750015B2 (en) *	2005-05-17	2010-07-06	Schering Corporation	Nitrogen-containing heterocyclic compounds and methods of use thereof
KR20080016567A (ko) *	2005-05-17	2008-02-21	쉐링 코포레이션	지질혈증장애의 치료를 위한 니코틴산 수용체 효능제로서의헤테로사이클
US7737155B2 (en)	2005-05-17	2010-06-15	Schering Corporation	Nitrogen-containing heterocyclic compounds and methods of use thereof
WO2007027532A2 (en) *	2005-08-29	2007-03-08	Merck & Co., Inc.	Niacin receptor agonists, compositions containing such compounds and methods of treatment
CA2620864A1 (en) *	2005-09-01	2007-03-08	Array Biopharma Inc.	Raf inhibitor compounds and methods of use thereof
WO2007042035A2 (en) *	2005-10-07	2007-04-19	Aditech Pharma Ab	Combination therapy with fumaric acid esters for the treatment of autoimmune and/or inflammatory disorders
AU2006331770A1 (en) *	2005-12-21	2007-07-05	Schering Corporation	Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and H3 receptor antagonist/inverse agonist
WO2007075555A2 (en) *	2005-12-21	2007-07-05	Schering Corporation	Combination of an h3 antagonist/inverse agonist and an appetite suppressant
US7763623B2 (en) *	2006-01-20	2010-07-27	Schering Corporation	Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
US20090069275A1 (en) *	2006-02-17	2009-03-12	Rocca Jose G	Low flush niacin formulation
JP2010503672A (ja)	2006-09-15	2010-02-04	シェーリングコーポレイション	脂質代謝障害、疼痛、糖尿病、および他の障害を治療するためのスピロ環アゼチジノン誘導体
CA2663502A1 (en) *	2006-09-15	2008-03-20	Schering Corporation	Azetidinone derivatives and methods of use thereof
CN101528227A (zh) *	2006-09-15	2009-09-09	先灵公司	氮杂环丁酮衍生物及其使用方法
WO2008039882A1 (en) *	2006-09-30	2008-04-03	Sanofi-Aventis U.S. Llc	A combination of niacin and a prostaglandin d2 receptor antagonist
EP2114154B1 (en) *	2007-02-08	2013-08-28	Merck Sharp & Dohme Corp.	Method of treating atherosclerosis, dyslipidemias and related conditions
US20090076117A1 (en) *	2007-09-17	2009-03-19	Protia, Llc	Deuterium-enriched laropiprant
CN101559058B (zh) *	2008-04-16	2011-07-20	北京本草天源药物研究院	一种治疗血脂异常的药物组合物
US20100015220A1 (en) *	2008-05-20	2010-01-21	Wetterau John R	Niacin and nsaid combination therapy
WO2010030360A1 (en)	2008-09-11	2010-03-18	Arena Pharmaceuticals, Inc.	3H-IMIDAZO[4,5-b]PYRIDIN-5-OL DERIVATIVES USEFUL IN THE TREATMENT OF GPR81 RECEPTOR DISORDERS
EP2341773A4 (en) *	2008-09-24	2012-03-07	Merck Sharp & Dohme	PHARMACEUTICAL COMPOSITIONS FROM ATORVASTATIN
WO2010075068A1 (en)	2008-12-16	2010-07-01	Schering Corporation	Pyridopyrimidine derivatives and methods of use thereof
EP2379562A1 (en)	2008-12-16	2011-10-26	Schering Corporation	Bicyclic pyranone derivatives as nicotinic acid receptor agonists
HUE030169T2 (en)	2009-01-09	2017-05-29	Forward Pharma As	Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
EP2547672A1 (en)	2010-03-16	2013-01-23	Aventis Pharmaceuticals Inc.	Substituted pyrimidines as prostaglandin d2 receptor antagonists
JP2013522307A (ja)	2010-03-16	2013-06-13	アベンティス・ファーマスーティカルズ・インコーポレイテツド	プロスタグランジンｄ２受容体アンタゴニストとしての置換ピリミジン
ES2991300T3 (es)	2015-02-13	2024-12-03	Inserm Institut Nat De La Sante Et De Larecherche Medicale	Antagonistas de PTGDR-1 y/o PTGDR-2 para prevenir y/o tratar lupus eritematoso sistémico

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3535326A (en) *	1967-03-06	1970-10-20	Sumitomo Chemical Co	Certain tetrahydro carboline derivatives
BE787444A (fr) *	1971-08-13	1973-02-12	Hoffmann La Roche	Composes polycycliques
US4009181A (en) *	1973-01-22	1977-02-22	Hoffmann-La Roche Inc.	Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof
US4057559A (en) *	1973-10-01	1977-11-08	American Home Products Corporation	Carbazole acetic acid derivatives
US4166452A (en)	1976-05-03	1979-09-04	Generales Constantine D J Jr	Apparatus for testing human responses to stimuli
US4256108A (en)	1977-04-07	1981-03-17	Alza Corporation	Microporous-semipermeable laminated osmotic system
GB2076242B (en)	1977-09-30	1982-10-20	Rca Corp	Television system scheduler
US4342767A (en)	1980-01-23	1982-08-03	Merck & Co., Inc.	Hypocholesteremic fermentation products
US4444784A (en)	1980-08-05	1984-04-24	Merck & Co., Inc.	Antihypercholesterolemic compounds
US4265874A (en)	1980-04-25	1981-05-05	Alza Corporation	Method of delivering drug with aid of effervescent activity generated in environment of use
DK149080C (da)	1980-06-06	1986-07-28	Sankyo Co	Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US5354772A (en)	1982-11-22	1994-10-11	Sandoz Pharm. Corp.	Indole analogs of mevalonolactone and derivatives thereof
US4808608A (en) *	1986-01-23	1989-02-28	Merck & Co., Inc.	Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
US5021447A (en) *	1986-01-23	1991-06-04	Merck Frosst Canada, Inc.	Tetrahydrocarbazole 1-alkanoic acids and pharmaecutical compositions
US4940719A (en) *	1986-03-27	1990-07-10	Merck Frosst Canada, Inc.	Tetrahydrocarbazole esters, pharmaceutical compositions and use
US4775680A (en) *	1987-07-21	1988-10-04	Merck & Co., Inc.	Cyclohept[b]indolealkanoic acids, pharmaceutical compositions and use
FI94339C (fi)	1989-07-21	1995-08-25	Warner Lambert Co	Menetelmä farmaseuttisesti käyttökelpoisen /R-(R,R)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
JP2648897B2 (ja)	1991-07-01	1997-09-03	塩野義製薬株式会社	ピリミジン誘導体
US5190972A (en) *	1992-01-27	1993-03-02	The University Of Melbourne	Method of combatting cyclosporine organ toxicity with prostaglandin analogs
US5631365A (en)	1993-09-21	1997-05-20	Schering Corporation	Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
AU5787996A (en) *	1995-04-19	1996-11-07	Lipoprotein Technologies, Inc.	Compositions, kits, and methods for administration of antilipemic and anti-platelet aggregation drugs
MY114803A (en)	1995-10-31	2003-01-31	Schering Corp	Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
WO1997016424A1 (en)	1995-11-02	1997-05-09	Schering Corporation	Process for preparing 1-(4-fluorophenyl)-3(r)-(3(s)-hydroxy-3-([phenyl or 4-fluorophenyl])-propyl)-4(s)-(4-hydroxyphenyl)-2-azetidinone
DE122011000014I1 (de)	1995-12-22	2011-11-03	Kowa Co	Pharmazeutische zusammensetzung stabilisiert mit einem basischen medium.
US5886171A (en)	1996-05-31	1999-03-23	Schering Corporation	3-hydroxy gamma-lactone based enantioselective synthesis of azetidinones
US5739321A (en)	1996-05-31	1998-04-14	Schering Corporation	3-hydroxy γ-lactone based enantionselective synthesis of azetidinones
US5756470A (en)	1996-10-29	1998-05-26	Schering Corporation	Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
US6469035B1 (en) *	1997-07-31	2002-10-22	Eugenio A. Cefali	Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid
US20010006644A1 (en) *	1997-07-31	2001-07-05	David J. Bova	Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
AU752673B2 (en) *	1997-07-31	2002-09-26	Abbott Laboratories	Combinations of HMG-CoA reductase inhibitors and nicotinic acid compounds and methods for treating hyperlipidemia once a day at night
HUP0101110A3 (en) *	1997-10-27	2002-06-28	Reddys Lab Ltd Dr	Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them
US6133001A (en)	1998-02-23	2000-10-17	Schering Corporation	Stereoselective microbial reduction for the preparation of 1-(4-fluorophenyl)-3(R)-[3(S)-Hydroxy-3-(4-fluorophenyl)propyl)]-4(S)-(4 -hydroxyphenyl)-2-azetidinone
US5919672A (en)	1998-10-02	1999-07-06	Schering Corporation	Resolution of trans-2-(alkoxycarbonylethyl)-lactams useful in the synthesis of 1-(4-fluoro-phenyl)-3(R)- (S)-hydroxy-3-(4-fluorophenyl)-propyl!-4(S)-(4-hydroxyphenyl)-2-azetidinone
CA2353981C (en)	1998-12-07	2005-04-26	Schering Corporation	Process for the synthesis of azetidinones
NZ512532A (en)	1998-12-23	2003-12-19	G	Combinations for treating cardiovascular diseases like hypercholesterolemia and atherosclerosis
AU3382699A (en)	1999-04-05	2000-10-23	Schering Corporation	Stereoselective microbial reduction for the preparation of - (4-fluorophenyl) - 3(r)-(3(s) - hydroxy-3 (4-fluorophenyl) propyl))-4(s) (4-hydroxyphenyl)-2-azetidinone
US6593078B1 (en)	1999-04-16	2003-07-15	Schering Corporation	Use of azetidinone compounds
IT1306141B1 (it) *	1999-05-17	2001-05-30	Giampiero Valletta	Composizione per il trattamento del prurito uremico e di forme diprurito non riconducibili a lesioni organiche.
JP4292742B2 (ja)	2000-03-09	2009-07-08	小野薬品工業株式会社	インドール誘導体、その製造方法および用途
US20010047027A1 (en) *	2000-04-12	2001-11-29	Marc Labelle	Prostaglandin D2 receptor antagonists
JP2002008186A (ja) *	2000-06-23	2002-01-11	Mitsubishi Heavy Ind Ltd	車種識別装置
US6410583B1 (en)	2000-07-25	2002-06-25	Merck Frosst Canada & Co.	Cyclopentanoindoles, compositions containing such compounds and methods of treatment
JP3889563B2 (ja) *	2000-09-13	2007-03-07	三洋電機株式会社	映像信号処理回路
EP1377834A2 (en)	2001-04-11	2004-01-07	Glaxo Group Limited	Medicaments which are modulators of hm74 and/or hm74a activity
JP4279561B2 (ja) *	2001-05-23	2009-06-17	メルクフロストカナダリミテツド	プロスタグランジンＤ２受容体拮抗薬としてのジヒドロピロロ［１，２−ａ］インドールおよびテトラヒドロピリド［１，２−ａ］−インドール誘導体
EP1424335A4 (en)	2001-09-07	2005-11-16	Ono Pharmaceutical Co	INDOLE DERIVATIVES
AR038136A1 (es) *	2002-01-24	2004-12-29	Merck Frosst Canada Inc	Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
BR0308518A (pt)	2002-03-19	2005-02-22	Ono Pharmaceutical Co	Compostos ácidos carboxìlicos e drogas contendo os compostos como o ingrediente ativo
KR20050012771A (ko) *	2002-06-03	2005-02-02	노파르티스 아게	치환된 시아노피롤리딘의 용도 및 이들을 함유하는고지혈증 및 관련 질환의 치료를 위한 조합 제제
US7019022B2 (en) *	2003-12-15	2006-03-28	Merck Frosst Canada & Co.	Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
JP4129960B2 (ja) *	2005-07-01	2008-08-06	タキゲン製造株式会社	ステー

2004
- 2004-05-05 AR ARP040101527A patent/AR041089A1/es unknown
- 2004-05-06 PE PE2004000463A patent/PE20050552A1/es not_active Application Discontinuation
- 2004-05-06 JO JO200454A patent/JO2564B1/en active
- 2004-05-10 MY MYPI20041729A patent/MY140639A/en unknown
- 2004-05-13 MX MXPA05012272A patent/MXPA05012272A/es active IP Right Grant
- 2004-05-13 WO PCT/US2004/014980 patent/WO2004103370A1/en not_active Ceased
- 2004-05-13 EP EP04785539A patent/EP1624871B1/en not_active Expired - Lifetime
- 2004-05-13 PL PL04785539T patent/PL1624871T3/pl unknown
- 2004-05-13 PL PL09163448T patent/PL2116244T3/pl unknown
- 2004-05-13 SG SG200708456-9A patent/SG153667A1/en unknown
- 2004-05-13 DK DK04785539T patent/DK1624871T3/da active
- 2004-05-13 PT PT04785539T patent/PT1624871E/pt unknown
- 2004-05-13 GE GEAP20049114A patent/GEP20084569B/en unknown
- 2004-05-13 DK DK09163448.5T patent/DK2116244T3/da active
- 2004-05-13 RS RS20120499A patent/RS20120499A1/sr unknown
- 2004-05-13 CN CNB2004800128531A patent/CN100441184C/zh not_active Expired - Fee Related
- 2004-05-13 NZ NZ543399A patent/NZ543399A/en not_active IP Right Cessation
- 2004-05-13 US US10/844,773 patent/US20040229844A1/en not_active Abandoned
- 2004-05-13 KR KR1020057021795A patent/KR100806008B1/ko not_active Expired - Lifetime
- 2004-05-13 RS RS20120498A patent/RS20120498A1/sr unknown
- 2004-05-13 CA CA2525772A patent/CA2525772C/en not_active Expired - Fee Related
- 2004-05-13 ES ES09163448T patent/ES2392743T3/es not_active Expired - Lifetime
- 2004-05-13 ES ES04785539T patent/ES2328148T3/es not_active Expired - Lifetime
- 2004-05-13 CN CN2008101690579A patent/CN101559227B/zh not_active Expired - Fee Related
- 2004-05-13 AU AU2004240597A patent/AU2004240597B2/en not_active Ceased
- 2004-05-13 PT PT09163448T patent/PT2116244E/pt unknown
- 2004-05-13 EP EP10182413A patent/EP2286816A1/en not_active Withdrawn
- 2004-05-13 EP EP09163448A patent/EP2116244B1/en not_active Expired - Lifetime
- 2004-05-13 EA EA200702674A patent/EA011895B1/ru not_active IP Right Cessation
- 2004-05-13 RS YU20050777A patent/RS52731B/sr unknown
- 2004-05-13 NZ NZ572515A patent/NZ572515A/en not_active IP Right Cessation
- 2004-05-13 DE DE602004022036T patent/DE602004022036D1/de not_active Expired - Lifetime
- 2004-05-13 SI SI200431221T patent/SI1624871T1/sl unknown
- 2004-05-13 UA UAA200512018A patent/UA89615C2/ru unknown
- 2004-05-13 GE GEAP200410277A patent/GEP20105025B/en unknown
- 2004-05-13 JP JP2006515355A patent/JP4637833B2/ja not_active Expired - Fee Related
- 2004-05-13 KR KR1020077029888A patent/KR100960749B1/ko not_active Expired - Fee Related
- 2004-05-13 EA EA200501817A patent/EA009744B1/ru not_active IP Right Cessation
- 2004-05-13 GT GT200400098A patent/GT200400098A/es unknown
- 2004-05-13 SI SI200431951T patent/SI2116244T1/sl unknown
- 2004-05-13 CN CN2012100149106A patent/CN102526735A/zh active Pending
- 2004-05-13 HR HR20090424T patent/HRP20090424T1/xx unknown
- 2004-05-13 ME MEP-601/08A patent/MEP60108A/xx unknown
- 2004-05-13 BR BRPI0410273-8A patent/BRPI0410273A/pt not_active IP Right Cessation
- 2004-05-14 PA PA20048603201A patent/PA8603201A1/es unknown
- 2004-05-14 TW TW093113730A patent/TWI334354B/zh not_active IP Right Cessation
- 2004-05-14 DO DO2004000907A patent/DOP2004000907A/es unknown
- 2004-05-14 HN HN2004000171A patent/HN2004000171A/es unknown
- 2004-05-14 TW TW096125297A patent/TWI341199B/zh not_active IP Right Cessation
- 2004-05-14 CL CL200401056A patent/CL2004001056A1/es unknown
2005
- 2005-10-13 IS IS8071A patent/IS2708B/is unknown
- 2005-10-13 ZA ZA200508288A patent/ZA200508288B/xx unknown
- 2005-10-19 CR CR8047A patent/CR8047A/es unknown
- 2005-11-09 MA MA28589A patent/MA27835A1/fr unknown
- 2005-11-10 CO CO05114676A patent/CO5630034A2/es active IP Right Grant
- 2005-11-11 EC EC2005006156A patent/ECSP056156A/es unknown
- 2005-11-14 TN TNP2005000290A patent/TNSN05290A1/en unknown
- 2005-11-14 IL IL171962A patent/IL171962A/en not_active IP Right Cessation
- 2005-12-14 NO NO20055957A patent/NO20055957L/no not_active Application Discontinuation
2008
- 2008-03-11 CR CR9808A patent/CR9808A/es not_active Application Discontinuation
2009
- 2009-05-21 US US12/470,049 patent/US20090233977A1/en not_active Abandoned
- 2009-10-13 CY CY20091101051T patent/CY1109476T1/el unknown
- 2009-11-30 US US12/627,787 patent/US20100076002A1/en not_active Abandoned
- 2009-12-02 JP JP2009274146A patent/JP2010077151A/ja active Pending
2011
- 2011-01-24 US US13/012,696 patent/US20110118292A1/en not_active Abandoned
- 2011-03-07 AU AU2011200986A patent/AU2011200986B2/en not_active Ceased
2012
- 2012-10-11 HR HRP20120818TT patent/HRP20120818T1/hr unknown
- 2012-11-05 CY CY20121101050T patent/CY1113342T1/el unknown

Also Published As

Publication number	Publication date
NZ572515A (en)	2010-07-30
SI2116244T1 (sl)	2012-12-31
MEP60108A (en)	2011-05-10
PE20050552A1 (es)	2005-08-06
AU2004240597B2 (en)	2011-01-06
US20110118292A1 (en)	2011-05-19
DK2116244T3 (da)	2012-11-26
HK1092722A1 (zh)	2007-02-16
CN101559227A (zh)	2009-10-21
EA009744B1 (ru)	2008-04-28
JP4637833B2 (ja)	2011-02-23
WO2004103370A1 (en)	2004-12-02
IS2708B (is)	2011-01-15
US20040229844A1 (en)	2004-11-18
JO2564B1 (en)	2010-11-03
JP2010077151A (ja)	2010-04-08
GEP20084569B (en)	2008-12-25
EP2116244A1 (en)	2009-11-11
AU2011200986A1 (en)	2011-03-31
GEP20105025B (en)	2010-06-25
CL2004001056A1 (es)	2005-03-28
HN2004000171A (es)	2011-07-11
GT200400098A (es)	2005-03-03
TW200803844A (en)	2008-01-16
CO5630034A2 (es)	2006-04-28
IL171962A (en)	2012-06-28
HRP20090424T1 (en)	2009-09-30
KR100960749B1 (ko)	2010-06-01
HRP20120818T1 (hr)	2012-11-30
CN1787819A (zh)	2006-06-14
KR20060012617A (ko)	2006-02-08
ES2328148T3 (es)	2009-11-10
CA2525772C (en)	2011-03-15
PT1624871E (pt)	2009-09-07
PA8603201A1 (es)	2005-02-04
CY1109476T1 (el)	2014-08-13
ES2392743T3 (es)	2012-12-13
EP2116244B1 (en)	2012-08-08
TW200503757A (en)	2005-02-01
CN101559227B (zh)	2012-03-21
EP1624871A1 (en)	2006-02-15
DE602004022036D1 (de)	2009-08-27
CN102526735A (zh)	2012-07-04
DOP2004000907A (es)	2004-11-30
NO20055957L (no)	2006-02-14
EA200702674A1 (ru)	2008-04-28
CA2525772A1 (en)	2004-12-02
KR100806008B1 (ko)	2008-02-26
EP1624871B1 (en)	2009-07-15
CN100441184C (zh)	2008-12-10
EP2286816A1 (en)	2011-02-23
ECSP056156A (es)	2006-04-19
CR8047A (es)	2006-07-14
IL171962A0 (en)	2006-04-10
PL2116244T3 (pl)	2013-01-31
AR041089A1 (es)	2005-05-04
TNSN05290A1 (en)	2007-07-10
RS20120498A1 (sr)	2013-08-30
PL1624871T3 (pl)	2009-12-31
RS20120499A1 (sr)	2013-08-30
AU2004240597A1 (en)	2004-12-02
US20090233977A1 (en)	2009-09-17
TWI334354B (en)	2010-12-11
UA89615C2 (ru)	2010-02-25
NZ543399A (en)	2009-02-28
EA200501817A1 (ru)	2006-06-30
US20100076002A1 (en)	2010-03-25
RS52731B (sr)	2013-08-30
BRPI0410273A (pt)	2006-05-16
CY1113342T1 (el)	2016-06-22
JP2006526030A (ja)	2006-11-16
EA011895B1 (ru)	2009-06-30
CR9808A (es)	2008-07-29
PT2116244E (pt)	2012-11-02
MY140639A (en)	2010-01-15
MXPA05012272A (es)	2006-05-19
TWI341199B (en)	2011-05-01
SI1624871T1 (sl)	2009-12-31
ZA200508288B (en)	2008-08-27
MA27835A1 (fr)	2006-04-03
SG153667A1 (en)	2009-07-29
RS20050777A (sr)	2008-04-04
AU2011200986B2 (en)	2012-11-08
KR20080003470A (ko)	2008-01-07
DK1624871T3 (da)	2009-11-16

Publication	Publication Date	Title
IS8071A (is)	2005-10-13	Aðferð við meðhöndlun á hnútahersli, fitudreyra og tengdum ástands tegundum og lyfjafræðilegum samsetningum
IS8142A (is)	2005-11-23	Læknislyf gagnleg til meðferðar á verkjum
IS8267A (is)	2006-01-26	[1,8]naftýridín-2-ón og tengd efnasambönd til notkunar við meðferð á geðklofa
IS7684A (is)	2005-02-03	Ný efnasambönd, blöndur og aðferðir til að meðhöndla bólgusjúkdóma og -ástand
EA200500098A1 (ru)	2005-08-25	Лекарственное средство и способ лечения патологического синдрома
DE502004002801D1 (de)	2007-03-15	Bohrlochbehandlungsmittel, enthaltend ethercarbonsäuren
NO20052760D0 (no)	2005-06-07	Fremgangsmate for behandling av kreft og beslektede fremgangsmater.
IS2722B (is)	2011-03-15	1, 2, 3, 4- Tetrasetin indól til meðhöndlunar á öndunarfærasjúkdómum
EP1696877A4 (en)	2010-06-09	PROCESS FOR PAIN TREATMENT
NO20043839L (no)	2004-11-12	Havbunnsbasert intervensjonssystem, fremgangsmate for og komponeter i dette
ITMO20040191A1 (it)	2004-10-23	Macchina e metodo per il trattamento extracorporeo di sangue.
IS7648A (is)	2005-01-13	Dífenýlasetídínónafleiður til að meðhöndla fituefnaskiptasjúkdóma
DE60308431D1 (de)	2006-11-02	Geschäumte Säurebehandlungsflüssigkeit
NO20032220D0 (no)	2003-05-15	Löfteverktöy II og fremgangsmåte for anvendelse av samme
NO20035156L (no)	2004-01-20	Fremgangsmåter for brønnbehandling
DE60239766D1 (de)	2011-05-26	Wärmebehandlungssystem
DE60322451D1 (de)	2008-09-04	4-Tetrazolyl-4-Phenylpiperidinderivate zur Schmerzbehandlung
NO20044195L (no)	2004-10-01	Biofosfoninsyrer for behandling og prevensjon av osteoprose
NO20045554L (no)	2004-12-20	Fremgangsmate for behandling av diabetes
IS6077A (is)	2001-09-18	Efnasambönd og aðferðir til meðhöndlunar á asma, ofnæmi og bólgutruflunum
IS7163A (is)	2004-02-26	Aðferðir til meðhöndlunar á lungnasjúkdómi
EP1651237A4 (en)	2008-10-01	METHODS OF TREATING DERMATOLOGICAL DISORDERS
ATE389742T1 (de)	2008-04-15	Gewebebehandlungsmittel
IS8497A (is)	2006-06-02	Aðferðir og hvarfefni til að meðhöndla bólgusjúkdóma
IS3004B (is)	2018-09-15	Aðferð til meðhöndlunar á svefnleysi á frumstigi